Evidence map›Paper›PMID 29179446›Full record

ArticleOncotarget2017

Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells.

Yeon-Jin Kwon, Boris A Leibovitch, Nidhi Bansal, Lutecia Pereira, Chi-Yeh Chung, Edgardo V Ariztia, Arthur Zelent, Eduardo F Farias, Samuel Waxman

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).International journal of molecular sciences · 2020
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yeon-Jin KwonIcahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Boris A LeibovitchIcahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Nidhi BansalIcahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Lutecia PereiraUniversity of Miami, Sylvester Comprehensive Cancer Center, Florida MI, USA.
Chi-Yeh ChungIcahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Edgardo V AriztiaIcahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Arthur ZelentUniversity of Miami, Sylvester Comprehensive Cancer Center, Florida MI, USA.
Eduardo F FariasIcahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Samuel WaxmanIcahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA.
Icahn School of Medicine at Mount Sinai · USSylvester Comprehensive Cancer Center · USTisch Hospital · US

Funding

THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
Targeted epigenetic therapy of triple-negative breast cancerR01CA158121 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WAXMAN, SAMUEL · 2011 to 2015
$1.6M
NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA158121
6 · The paper itself

Abstract

Cancer cell invasion is an obligatory step for metastatic dissemination that contributes to rapid relapse and a poorer survival in triple negative breast cancer (TNBC) patients. Development of novel therapeutic strategies to block tumor invasion is an unmet need in the treatment of cancer. We reported that the selective inhibition of the PAH2 domain of SIN3A protein function markedly suppressed metastatic dissemination to the lungs in TNBC xenograft bearing mice. Here, we show that TNBC cell lines treated with Sin3 interaction domain (SID) decoy peptides that bind to PAH2 display a strong

Indexed as

invasionmetastasisSIN3ATGIF1triple negative breast cancerWnt

Identifiers

PMID29179446
PMCPMC5687616
OpenAlexW2514663093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.